Efek Inhibitor Proteasom Terhadap Gambaran Histopatologi Jantung pada Tikus yang diinduksi Aterosklerosis

Ilhami Romus, Ismawati Ismawati, Indah Putri Arwandi

Abstract

Proteasome inhibitors are compounds that can inhibit the proteasome pathway in carrying out its functions. Proteasome inhibitors have a beneficial effect due to their anti-inflammatory properties. The proteasome inhibitor used in this study was bortezomib. This study aimed to analyze the effect of proteasome inhibitors on cardiac histopathology in atherosclerosis-induced rats. This study used male Rattus novergicus Wistar strain which was divided into 3 groups, namely the control group, the atherosclerosis-induced group and the atherosclerosis-induced group and given bortezomib. The results obtained the mean scores of edema, inflammation and necrosis in the atherosclerosis group were given bortezomib at a dose of 50 g/kgBW were less than the atherosclerosis group. Theese difference were statistically significant  (p<0.05). This study concluded that the administration of bortezomib can reduce the Impact of atherosclerotic lesions on the heart muscle.

Keywords

Atherosclerosis, Bortezomib, Histopathology, Heart

References

Kemenkes RI. Situasi kesehatan jantung. Pusat data dan informasi Kementeri Kesehat RI [Internet]. 2014;3. Available from: http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-jantung.pdf

Kementerian Kesehatan Republik Indonesia. Direktorat pencegahan dan pengendalian penyakit tidak menular Ditjen Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. 2020;(September).

Meidayanti D. Manfaat likopen dalam tomat sebagai pencegahan terhadap timbulnya aterosklerosis. J Med Hutama Vol 02 No 03. 2020;02(01):402–6.

Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5(8):927–46.

Kobiyama K, Ley K. Atherosclerosis a chronic inflammatory disease with an autoimmune component. Circ Res. 2018;123(10):1118–20.

Rahman A, Limantoro C, Purwoko Y. Faktor – faktor risiko mayor aterosklerosis pada berbagai penyakit aterosklerosis di Rsup Dr. Kariadi Semarang [Internet]. 2012 [cited 2022 Aug 2]. Available from: http://eprints.undip.ac.id/37389/

Sargowo D dr. SPSJ (K). Patogenesis aterosklerosis. UB Press. 2015. 165–180 p.

Ismawati, Oenzil F, Yanwirasti, Yerizel E. Changes in expression of proteasome in rats at different stages of atherosclerosis. Anat Cell Biol. 2016;49(2):99–106.

Ismawati, Romus I, Mukhyarjon, Salsabilqis J, Wulandari N. Effect of proteasome inhibitor on serum 8-OHdG and aortic SOD2 in a rat model of atherosclerosis. Bali Med J. 2022;11(1):391–6.

Ismawati I, Romus I, Utami EA. Efek inhibitor proteasom terhadap histopatologi arteri koronaria pada tikus model aterosklerosis. J Kedokt dan Kesehat [Internet]. 2020;16(2):135–42. Available from: https://jurnal.umj.ac.id/index.php/JKK/article/view/6062

Wilck N, Fechner M, Dreger H, Hewing B, Arias A, Meiners S, et al. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arterioscler Thromb Vasc Biol. 2012;32(6):1418–26.

Wilck N, Fechner M, Dan C, Stangl V, Stangl K, Ludwig A. The effect of low-dose proteasome inhibition on pre-existing atherosclerosis in LDL receptor-deficient mice. Int J Mol Sci. 2017;18(4).

Herrmann J, Lerman LO, Lerman A. On to the road to degradation: Atherosclerosis and the proteasome. Cardiovasc Res. 2010;85(2):291–302.

DOI: https://doi.org/10.26891/JIK.v17i1.2023.66-70

Refbacks

  • There are currently no refbacks.